Month: April 2022

SN Aboitiz Power Group (SNAP), a joint venture between Scatec and AboitizPower, has made the final investment decision for the 20 MW battery energy storage system (BESS) project at the Magat hydropower plant in Ramon, Isabela in the Philippines.   The project is now making final preparations for construction start later in 2022, with a targeted commercial operation date in 2024, and marks the first venture between the country’s leading provider of renewable energy AboitizPower and Scatec, after the Norwegian renewable energy solutions provider acquired SN Power. “We are excited about technologies like BESS that complement our ambition of bringing forth an RE-powered future, and continue to explore and assess other greenfield and brownfield opportunities beyond hydropower and floating solar. We also appreciate the support of our banking...

CGG and Kent Announce Strategic Carbon Capture & Hydrogen Partnership to Accelerate Global Decarbonisation Paris, France – April 5, 2022 CGG, a global technology leader in geoscience, has announced a strategic partnership with Kent, a leading energy services engineering company, to work together on realizing decarbonisation opportunities through CCUS development and hydrogen production and supply. CGG and Kent will be providing customers in the energy and industrial sectors with ‘end-to-end’ services across the life cycle of the projects. For example, from subsurface characterization required for storage screening and evaluation to project engineering, planning, construction, and commissioning, including late-life activities such as decommissioning and long-term monitoring, that include instrumentation and data management. This collaboration...

Press release Paris La Défense, 5 April 2022 Governance changes Marie-Claire Daveu has informed Albioma today of her intention to resign from the Board of Directors with effect from 31 July 2022, with her appointment as Director to be submitted to Engie’s General Meeting of Shareholders shortly. The composition of the Board of Directors of Albioma will be reviewed accordingly in the coming months. Frédéric Moyne, Chairman and CEO of Albioma, said: “I would like to join all the directors in thanking Marie-Claire Daveu for her outstanding contribution to the work of the Board, particularly in her role as Chair of the Corporate Social Responsibility Committee. She has been one of the key players in the Group’s excellence in sustainable development.” Next on the agenda: revenue figures for the first quarter of the 2022 financial...

Figure 1 Kaplan Meier – Preliminary survival rate analysis of Roll-In Cohort, dated 25 March 2022Reporting of primary endpoint on track for Q4 2022 FDA regulatory submission on track for mid-202370% survival of POSEIDON Roll-In patients at one year post-implantation1 compares favourably to published literature in this high-risk patient populationGHENT, Belgium, April 05, 2022 (GLOBE NEWSWIRE) — Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites, and heart failure, today announces that it has completed implanting patients in POSEIDON, the North American pivotal study to support regulatory approval of the alfapump system in the U.S. and Canada, for the treatment of...

Four-year collaboration to investigate the potential of IBA’s ConformalFLASH® technology for the treatment of early-stage breast cancer Louvain-la-Neuve, Belgium, April 5, 2022 IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, and the University Medical Center Groningen (UMCG) announce today a four-year research collaboration agreement towards development of a new FLASH irradiation protocol for the treatment of early-stage breast cancer. The focus of the partnership will be on building advanced FLASH irradiation techniques and pre-clinical radiobiology models to accelerate the validation and adoption of IBA’s ConformalFLASH®1 technology for use in pre-operative early breast cancer treatment. ConformalFLASH® is a novel delivery technique combining ultra-high dose rate FLASH radiotherapy with...

OSLO, Norway (5 April 2022) – TGS, a global provider of energy data and intelligence, today announced the start of a new 3D reprocessing project offshore Malaysia, the first stage of which will cover a 16,957 square kilometer area, integrating existing 3D seismic data offshore Peninsular Malaysia. Thirty-six 3D seismic surveys of varying vintages covering a key part of the Malay Basin will be processed through a high-end comprehensive broadband workflow by TGS’ consortium partner DownUnder GeoSolutions (DUG) in their Kuala Lumpur processing center. The workflow, which includes FWI, Q-Migration, and Q-Tomo, will create a single contiguous 3D volume and represents the only way oil and gas companies can access a modern regional scale dataset to evaluate the Malay Basin. This new dataset will allow for improved play mapping and...

         Interim data suggest long-term treatment with VYVGART provides improvement in generalized myasthenia gravis (gMG) disease scores that remains consistent over multiple treatment cycles Long-term safety profile of VYVGART treatment consistent with Phase 3 ADAPT study VYVGART is the first-and-only approved neonatal Fc receptor (FcRn) blocker Breda, the Netherlands—April 5, 2022—argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced interim results from ADAPT+, an ongoing Phase 3, open-label, three-year extension study evaluating long-term safety, tolerability and efficacy of VYVGART® (efgartigimod alfa-fcab) for the treatment of adults with gMG. The data will be presented today in an oral presentation at the 74th Annual...

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE U.S. CALGARY, Alberta., April 05, 2022 (GLOBE NEWSWIRE) — Acceleware Ltd. (“Acceleware”) (TSXV: AXE), a Canadian clean-tech innovator of radio frequency (RF) heating technologies today announced that it has closed its second non-brokered private placement of 10% unsecured convertible debentures due 2026 (the “Debentures”), for gross proceeds of $715,000 (the “Private Placement”). Details of the Private Placement Each Debenture matures four years after the issue date and is convertible into units of Acceleware at a conversion price of $0.80. If Acceleware subsequently sells common shares (or securities that are convertible into or exchangeable for common shares) at a lower purchase (or conversion) price, the conversion price of the Debentures will be adjusted...

Clearance of critical milestone expands capability for production of gene therapies, starting with Zolgensma®Basel, April 5, 2022 – Novartis today announced the U.S. Food and Drug Administration (FDA) has granted commercial licensure approval for its Durham, N.C. site, a multi-product gene therapy manufacturing facility. This approval allows the state-of-the-art, 170,000 square-foot facility to make, test and release commercial Zolgensma, as well as produce gene therapy product for current and future clinical trials. The clearance of this milestone brings online the second commercially-licensed manufacturing facility for Novartis Gene Therapies, joining the Libertyville, Ill. site, which was approved for Zolgensma® (onasemnogene abeparvovec) manufacturing and distribution in 2019. The Durham site will build on Novartis Gene Therapies’...

Enters into Cooperation Agreement with Indaba Capital Management CHARLESTON, S.C., April 04, 2022 (GLOBE NEWSWIRE) — Benefitfocus, Inc. (NASDAQ: BNFT) (“Benefitfocus” or the “Company”), today announced that it has entered into a cooperation agreement with Indaba Capital Management, L.P. (“Indaba”), which owns approximately 11.8% of the Company’s outstanding shares, making it one of the Company’s largest common stockholders. Under the terms of the agreement, Benefitfocus has appointed Alexander Lerner, Investment Partner at Indaba, to the Board of Directors, effective immediately, and agreed to include Mr. Lerner on its recommended slate of nominees for election at the Company’s 2022 Annual Meeting of Stockholders. Mr. Lerner will serve as Co-Chair of each of the Board’s Nominating and Governance committee and Strategy and...